Literature DB >> 15636426

Effects of dehydroepiandrosterone (DHEA) supplementation on hormonal, metabolic and behavioral status in patients with hypoadrenalism.

R Libè1, L Barbetta, C Dall'Asta, F Salvaggio, C Gala, P Beck-Peccoz, B Ambrosi.   

Abstract

Oral DHEA administration to patients with hypoadrenalism, in addition to glucocorticoid and mineralcorticoid replacement, may improve both well-being and hormonal/metabolic parameters. Twenty patients (13 men, 7 women, 26-76 yr, 11 with Addison's disease, 9 with central hypoadrenalism) were recruited in a placebo-controlled, randomized study. Hormone levels, carbohydrate and lipid parameters, bone metabolism, body composition and psychological parameters were evaluated at baseline and after treatment with DHEA 50 mg/day or placebo for 4 months. After 4 months of DHEA administration, serum DHEAS levels raised both in men (from 0.71+/-0.18 to 8.28+/-1.66 micropmol/l, p<0.005) and in women (from 0.25+/-0.07 to 5.65+/-1.93 micromol/l, p<0.05). Only in hypoadrenal women an increase in testosterone (T; from 0.4+/-0.1 to 1.45+/-0.26 nmol/l, p<0.05) and androstenedione (A; from 0.86+/-0.34 to 2.05+/-0.29 nmol/l, p<0.05) levels was observed. In men no significant modifications in T and 17-hydroxyprogesterone (17-OHP) levels were found, whereas serum SHBG significantly decreased. As far as the metabolic parameters are concerned, only in patients with Addison's disease a significant decrease in total cholesterol and in low-density lipoproteins after 4 months of DHEA administration was found. No changes in glucose metabolism and insulin sensitivity were observed. In basal conditions, mean serum osteocalcin (OC) was normal and significantly decreased after DHEA treatment. A significant reduction in body fat mass percentage (BF%) after DHEA administration was observed. As far as well-being is concerned, DHEA replacement did not cause any relevant variation of subjective health scales and sexuality in both sexes. Our study confirms that DHEA may be beneficial for female patients with hypoadrenalism, mainly in restoring androgen levels. Concerning the health status, more sensitive and specific instruments to measure the effects of DHEA treatment could be necessary.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15636426     DOI: 10.1007/BF03347515

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  27 in total

1.  Treatment of systemic lupus erythematosus with dehydroepiandrosterone: 50 patients treated up to 12 months.

Authors:  R F van Vollenhoven; L M Morabito; E G Engleman; J L McGuire
Journal:  J Rheumatol       Date:  1998-02       Impact factor: 4.666

2.  Dehydroepiandrosterone replacement in women with adrenal insufficiency.

Authors:  W Arlt; F Callies; J C van Vlijmen; I Koehler; M Reincke; M Bidlingmaier; D Huebler; M Oettel; M Ernst; H M Schulte; B Allolio
Journal:  N Engl J Med       Date:  1999-09-30       Impact factor: 91.245

3.  Replacement of dehydroepiandrosterone in adrenal failure: no benefit for subjective health status and sexuality in a 9-month, randomized, parallel group clinical trial.

Authors:  Kristian Løvås; Gennet Gebre-Medhin; Thor S Trovik; Kristian J Fougner; Sverre Uhlving; Bjørn G Nedrebø; Ole L Myking; Olle Kämpe; Eystein S Husebye
Journal:  J Clin Endocrinol Metab       Date:  2003-03       Impact factor: 5.958

4.  SCL-90: an outpatient psychiatric rating scale--preliminary report.

Authors:  L R Derogatis; R S Lipman; L Covi
Journal:  Psychopharmacol Bull       Date:  1973-01

5.  The Mini-Mental State Examination.

Authors:  M F Folstein; L N Robins; J E Helzer
Journal:  Arch Gen Psychiatry       Date:  1983-07

6.  Double-blind placebo-controlled trial of oral dehydroepiandrosterone in patients with advanced HIV disease.

Authors:  C Piketty; D Jayle; A Leplege; P Castiel; E Ecosse; G Gonzalez-Canali; B Sabatier; N Boulle; B Debuire; Y Le Bouc; E E Baulieu; M D Kazatchkine
Journal:  Clin Endocrinol (Oxf)       Date:  2001-09       Impact factor: 3.478

7.  Dehydroepiandrosterone supplementation and bone turnover in middle-aged to elderly men.

Authors:  Arnold J Kahn; Bernard Halloran; Owen Wolkowitz; Louann Brizendine
Journal:  J Clin Endocrinol Metab       Date:  2002-04       Impact factor: 5.958

8.  The effects of oral dehydroepiandrosterone on endocrine-metabolic parameters in postmenopausal women.

Authors:  J F Mortola; S S Yen
Journal:  J Clin Endocrinol Metab       Date:  1990-09       Impact factor: 5.958

9.  Dehydroepiandrosterone modulates endothelial nitric oxide synthesis via direct genomic and nongenomic mechanisms.

Authors:  Tommaso Simoncini; Paolo Mannella; Letizia Fornari; Gaetano Varone; Antonella Caruso; Andrea R Genazzani
Journal:  Endocrinology       Date:  2003-08       Impact factor: 4.736

10.  Replacement of DHEA in aging men and women. Potential remedial effects.

Authors:  S S Yen; A J Morales; O Khorram
Journal:  Ann N Y Acad Sci       Date:  1995-12-29       Impact factor: 5.691

View more
  6 in total

1.  Long-term DHEA replacement in primary adrenal insufficiency: a randomized, controlled trial.

Authors:  Eleanor M Gurnell; Penelope J Hunt; Suzanne E Curran; Catherine L Conway; Eleanor M Pullenayegum; Felicia A Huppert; Juliet E Compston; Joseph Herbert; V Krishna K Chatterjee
Journal:  J Clin Endocrinol Metab       Date:  2007-11-13       Impact factor: 5.958

Review 2.  [Replacement therapy with adrenal steroids].

Authors:  S Hahner; B Allolio
Journal:  Internist (Berl)       Date:  2008-05       Impact factor: 0.743

Review 3.  Therapy of adrenal insufficiency: an update.

Authors:  Alberto Falorni; Viviana Minarelli; Silvia Morelli
Journal:  Endocrine       Date:  2012-11-21       Impact factor: 3.633

4.  Effect of dehydroepiandrosterone supplementation on bone mineral density, bone markers, and body composition in older adults: the DAWN trial.

Authors:  D von Mühlen; G A Laughlin; D Kritz-Silverstein; J Bergstrom; R Bettencourt
Journal:  Osteoporos Int       Date:  2007-12-15       Impact factor: 4.507

5.  Digital Delivery of Meditative Movement Training Improved Health of Cigarette-Smoke-Exposed Subjects.

Authors:  Peter Payne; Steven Fiering; David Zava; Thomas J Gould; Anthony Brown; Paul Hage; Carole Gaudet; Mardi Crane-Godreau
Journal:  Front Public Health       Date:  2018-10-19

Review 6.  Central intracrine DHEA synthesis in ageing-related neuroinflammation and neurodegeneration: therapeutic potential?

Authors:  Y S L Powrie; C Smith
Journal:  J Neuroinflammation       Date:  2018-10-16       Impact factor: 8.322

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.